SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG have announced a strategic collaboration aimed at advancing the development of next-generation small molecule therapeutics targeting some of the most devastating degenerative diseases affecting global populations. The partnership brings together SynSmart’s expertise in synthetic and medicinal chemistry with Amporin’s innovative drug discovery platform, which focuses on restoring cellular membrane integrity disrupted by misfolded proteins.
Degenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, and type II diabetes continue to represent some of the most challenging areas in modern medicine. These conditions are often progressive, debilitating, and currently lack curative treatment options. The collaboration between the two companies seeks to address this unmet medical need by developing novel therapeutic candidates that target the root causes of cellular dysfunction rather than merely managing symptoms.
Under the terms of the agreement, SynSmart will take the lead in synthesizing a large and diverse library of innovative membrane-protecting small molecules. This work will be carried out at the company’s advanced research facility located in Mumbai, India. The goal of this effort is to generate a robust pool of candidate compounds that can be evaluated for their ability to stabilize and repair damaged cellular and mitochondrial membranes.
Once synthesized, these compounds will undergo rigorous screening processes to identify those with the highest potential for therapeutic efficacy. Depending on the outcomes of the initial screening phase, the collaboration may expand to include further optimization work, including follow-on chemistry to refine molecular properties. Additionally, there is potential to incorporate ADME-PK (Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics) studies to better understand how these compounds behave within biological systems. This integrated approach is designed to accelerate the progression of promising candidates toward clinical development and eventual selection as drug candidates.
The collaboration reflects a shared commitment to innovation, efficiency, and scientific excellence. SynSmart’s operational model, characterized by multi-shift laboratory operations and a streamlined organizational structure, enables rapid turnaround times and cost-effective research execution. This efficiency is particularly valuable in early-stage drug discovery, where speed and resource optimization can significantly influence project success.
Commenting on the partnership, Saurabh Kapure, Chief Executive Officer of SynSmart, emphasized the company’s ability to deliver high-value solutions to its partners. He noted that SynSmart’s flexible operating model allows for increased productivity while maintaining cost efficiency, enabling collaborators to achieve more within constrained budgets and timelines. According to Kapure, this collaboration serves as a strong validation of SynSmart’s capabilities and its growing reputation as a trusted partner in the global pharmaceutical and biotechnology ecosystem.
From Amporin’s perspective, the collaboration represents a critical step forward in advancing its proprietary drug discovery platform. Dr. Kelvin Stott, Founder and Chief Executive Officer of Amporin Pharmaceuticals AG, expressed enthusiasm about the partnership and its potential to accelerate the development of disease-modifying therapies. He highlighted the importance of being able to conduct cross-target screening and optimization in parallel, which can significantly enhance the efficiency of identifying effective treatments for multiple diseases simultaneously.
Amporin’s scientific approach is centered on addressing a fundamental mechanism underlying many degenerative diseases: the formation of holes or disruptions in cellular and mitochondrial membranes caused by misfolded proteins. These disruptions compromise the integrity and function of cells, ultimately leading to cell death and disease progression. Amporin’s small-molecule therapeutics are designed to block and repair these membrane defects, thereby restoring normal cellular function.
This mechanism of action represents a novel and potentially transformative approach to treating a wide range of diseases. By targeting a common underlying pathology, Amporin’s platform has the potential to generate therapies that are applicable across multiple indications. This includes not only well-known conditions such as ALS, Alzheimer’s, and Parkinson’s disease, but also numerous rare and orphan diseases that currently have limited treatment options.
SynSmart Rasayan Research Private Limited, as a contract research, development, and manufacturing organization (CRDMO), brings significant expertise and infrastructure to the collaboration. The company offers a range of services, including custom synthesis, medicinal chemistry, and specialized chemical technologies. Its client base includes more than 40 biotechnology companies and large pharmaceutical organizations, with projects typically structured under full-time equivalent (FTE) or fee-for-service (FFS) models.
The company has built a strong reputation for its capabilities in working with small molecules and complex peptides, as well as its adoption of advanced technologies such as photochemistry and flow chemistry. These capabilities enable SynSmart to tackle complex synthetic challenges and deliver high-quality compounds that meet the stringent requirements of modern drug discovery programs.
With a growing team of approximately 125 skilled chemists, SynSmart continues to expand its capacity and technical expertise. The company is also actively investing in emerging modalities and innovative approaches to drug discovery, positioning itself as a forward-looking partner for global pharmaceutical and biotechnology companies seeking to accelerate their research pipelines.
Amporin Pharmaceuticals AG, headquartered in Switzerland, is an emerging biotechnology company focused on developing a new class of small-molecule drugs. Its proprietary platform is designed to address the damage caused by misfolded proteins, which are implicated in a wide range of degenerative diseases. By repairing membrane damage and restoring cellular function, Amporin aims to not only halt disease progression but potentially reverse it.
The company’s approach has generated significant interest within the scientific and medical communities due to its potential to address multiple diseases through a single underlying mechanism. This broad applicability could lead to more efficient drug development processes and improved outcomes for patients suffering from currently incurable conditions.
The collaboration between SynSmart and Amporin highlights the increasing importance of strategic partnerships in the pharmaceutical and biotechnology industries. By combining complementary strengths and expertise, companies can accelerate innovation and overcome the complex challenges associated with drug discovery and development.
As the project progresses, both companies are expected to leverage their respective capabilities to drive the program forward. SynSmart’s role in compound synthesis and optimization will be critical in generating high-quality candidates, while Amporin’s platform and biological insights will guide the selection and advancement of the most promising therapies.
Ultimately, the success of this collaboration could have far-reaching implications for the treatment of degenerative diseases. If successful, the resulting therapies could offer new hope to millions of patients worldwide who currently face limited treatment options and poor prognoses.
In conclusion, the partnership between SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG represents a significant step forward in the pursuit of innovative treatments for some of the most challenging diseases of our time. By combining cutting-edge chemistry with novel biological insights, the collaboration aims to unlock new possibilities in drug discovery and deliver meaningful improvements in patient care.
Source link:https://www.businesswire.com/
